Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial

The ITACa trial was designed to define the role of cetuximab (Cet) and bevacizumab (Bev) in combination with standard chemotherapy (CT, FOLFIRI or FOLFOX4) as first- and second-line treatment in metastatic colorectal cancer. All patients with WT KRAS tumors who had been enrolled in the first-line tr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Rep
Egile Nagusiak: Passardi, Alessandro, Scarpi, Emanuela, Gelsomino, Fabio, Palladino, Maria Angela, Casadei Gardini, Andrea, Turci, Daniele, Chiuri, Vincenzo Emanuele, Mucciarini, Claudia, Tassinari, Davide, Ragazzini, Angela, Frassineti, Giovanni Luca, Valgiusti, Martina, Ulivi, Paola, Amadori, Dino
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5585399/
https://ncbi.nlm.nih.gov/pubmed/28874797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-11048-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak